MedTrace Logo

HFNC Versus Microstream Advance Nasal Cannula for Oxygenation During ERCP

NCT07611903 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2026-06-01

No results posted yet for this study

Summary

Endoscopic retrograde cholangiopancreatography (ERCP) procedures are commonly performed under deep sedation and are associated with a risk of hypoxemia, particularly in prone or semi-prone positions. High-flow nasal cannula (HFNC) therapy may improve oxygenation by delivering heated and humidified oxygen at high flow rates, while the Microstream Advance nasal cannula provides simultaneous nasal oxygen delivery and oral oxygen insufflation.

This prospective randomized study aims to compare the effectiveness of HFNC and Microstream Advance nasal cannula in maintaining oxygenation during ERCP procedures. Patients undergoing ERCP will be randomized into two groups receiving either HFNC or Microstream Advance nasal cannula oxygen support during sedation.

The primary outcomes are the incidence of desaturation and oxygen reserve index (ORi) measurements during the procedure. Secondary outcomes include time to achieve target ORi levels, respiratory complications, and procedure-related adverse events.

Conditions

  • Endoscopic Retrograde Cholangiopancreatography
  • Hypoxemia

Interventions

DEVICE

High-flow nasal canula

Heated and humidified high-flow oxygen therapy delivered through a nasal cannula during ERCP under sedation

DEVICE

Microstream advance nasal cannula

Oxygen support delivered through the Microstream Advance nasal cannula during ERCP under sedation.

Sponsors & Collaborators

  • Kocaeli University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-29
Primary Completion
2026-11-30
Completion
2026-12-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07611903 on ClinicalTrials.gov